{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T04:04:30Z","timestamp":1754193870247,"version":"3.41.2"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> In the absence of SARS-CoV-2 specific antiviral treatments, various repurposed pharmaceutical approaches are under investigation for the treatment of COVID-19. Antiviral drugs considered for this condition include atazanavir, remdesivir, lopinavir-ritonavir, and favipiravir. Whilst the combination of lopinavir and ritonavir has been previously linked to prolongation of the QT<jats:sub>c<\/jats:sub> interval on the ECG and risk of <jats:italic>torsades de pointes<\/jats:italic> arrhythmia, less is known in this regard about atazanavir, remdesivir, and favipiravir. Unwanted abnormalities of drug-induced QT<jats:sub>c<\/jats:sub> prolongation by diverse drugs are commonly mediated by a single cardiac anti-target, the hERG potassium channel. This computational modeling study was undertaken in order to explore the ability of these five drugs to interact with known determinants of drug binding to the hERG channel pore.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Atazanavir, remdesivir, ritonavir, lopinavir and favipiravir were docked to <jats:italic>in silico<\/jats:italic> models of the pore domain of hERG, derived from cryo-EM structures of hERG and the closely related EAG channel.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Atazanavir was readily accommodated in the open hERG channel pore in proximity to the S6 Y652 and F656 residues, consistent with published experimental data implicating these aromatic residues in atazanavir binding to the channel. Lopinavir, ritonavir, and remdesivir were also accommodated in the open channel, making contacts in a model-dependent fashion with S6 aromatic residues and with residues at the base of the selectivity filter\/pore helix. The ability of remdesivir (at 30 \u03bcM) to inhibit the channel was confirmed using patch-clamp recording. None of these four drugs could be accommodated in the closed channel structure. Favipiravir, a much smaller molecule, was able to fit within the closed channel and could adopt multiple binding poses in the open channel, but with few simultaneous interactions with key binding residues. Only favipiravir and remdesivir showed the potential to interact with lateral pockets below the selectivity filter of the channel.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> All the antiviral drugs studied here can, in principle, interact with components of the hERG potassium channel canonical binding site, but are likely to differ in their ability to access lateral binding pockets. Favipiravir's small size and relatively paucity of simultaneous interactions may confer reduced hERG liability compared to the other drugs. Experimental structure-function studies are now warranted to validate these observations.<\/jats:p>","DOI":"10.3389\/fcvm.2021.645172","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T04:21:06Z","timestamp":1620102066000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel\u2014A Drug Antitarget"],"prefix":"10.3389","volume":"8","author":[{"given":"Ehab","family":"Al-Moubarak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jules C.","family":"Hancox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2020","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1016\/S1473-3099(20)30923-3","article-title":"The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials","volume":"21","author":"Singh","year":"2020","journal-title":"Lancet Infect Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"m4709","DOI":"10.1136\/bmj.m4709","article-title":"Covid-19: moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy","volume":"371","author":"Mahase","year":"2020","journal-title":"BMJ."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov."},{"key":"B6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends."},{"key":"B8","doi-asserted-by":"publisher","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents."},{"key":"B9","doi-asserted-by":"publisher","first-page":"101738","DOI":"10.1016\/j.tmaid.2020.101738","article-title":"Full-length title: early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France","volume":"35","author":"Million","year":"2020","journal-title":"Travel Med Infect Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.16.20065920","article-title":"Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19","author":"Magagnoli","year":"2020","journal-title":"medRXiv [Preprint]."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/S0140-6736(20)31324-6","article-title":"Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","volume":"395","author":"Mehra","year":"","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.hrthm.2020.04.046","article-title":"Chloroquine-induced torsade de pointes in a COVID-19 patient","volume":"17","author":"Szekely","year":"2020","journal-title":"Heart Rhythm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw Open."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e00399","DOI":"10.1128\/AAC.00399-20","article-title":"Compounds with therapeutic potential against novel respiratory 2019. coronavirus","volume":"64","author":"Martinez","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/JCMA.0000000000000318","article-title":"Potential therapeutic agents against COVID-19: What we know so far","volume":"83","author":"Lu","year":"2020","journal-title":"J Chin Med Assoc."},{"key":"B17","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.csbj.2020.03.025","article-title":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model","volume":"18","author":"Beck","year":"2020","journal-title":"Comput Struct Biotechnol J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMc2008043","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/phar.2429","article-title":"Remdesivir: review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - preliminary report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"104859","DOI":"10.1016\/j.phrs.2020.104859","article-title":"Candidate drugs against SARS-CoV-2 and COVID-19","volume":"157","author":"McKee","year":"2020","journal-title":"Pharmacol Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/s41467-021-21992-w","article-title":"Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model","volume":"12","author":"Driouich","year":"2021","journal-title":"Nat Commun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering."},{"key":"B25","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1080\/07853890.2021.1875500","article-title":"Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review","volume":"53","author":"Wadaa-Allah","year":"2021","journal-title":"Ann Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.mayocp.2020.03.024","article-title":"Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19)","volume":"95","author":"Giudicessi","year":"2020","journal-title":"Mayo Clin Proc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fcvm.2020.00085","article-title":"COVID-19 management and arrhythmia: risks and challenges for clinicians treating patients affected by SARS-CoV-2","volume":"7","author":"Carpenter","year":"2020","journal-title":"Front Cardiovasc Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/2048872620922784","article-title":"Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol","volume":"9","author":"Naksuk","year":"2020","journal-title":"Eur Heart J Acute Cardiovasc Care."},{"key":"B29","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s15010-020-01448-x","article-title":"Early experience with remdesivir in SARS-CoV-2 pneumonia","volume":"48","author":"Durante-Mangoni","year":"2020","journal-title":"Infection."},{"key":"B30","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0140-6736(05)70936-3","article-title":"Blockade of HERG channels by HIV protease inhibitors","volume":"365","author":"Anson","year":"2005","journal-title":"Lancet."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1086\/511875","article-title":"Prolonged QT interval and torsades de pointes associated with atazanavir therapy","volume":"44","author":"Ly","year":"2007","journal-title":"Clin Infect Dis."},{"key":"B32","first-page":"104","article-title":"First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes","volume":"18","year":"2009","journal-title":"Prescrire Int"},{"key":"B33","doi-asserted-by":"publisher","first-page":"866","DOI":"10.5414\/CP202388","article-title":"Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults","volume":"53","author":"Kumagai","year":"2015","journal-title":"Int J Clin Pharmacol Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0006034","DOI":"10.1371\/journal.pntd.0006034","article-title":"QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient","volume":"11","author":"Chinello","year":"2017","journal-title":"PLoS Negl Trop Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nature04710","article-title":"hERG potassium channels and cardiac arrhythmia","volume":"440","author":"Sanguinetti","year":"2006","journal-title":"Nature."},{"key":"B36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.pharmthera.2008.05.009","article-title":"The hERG potassium channel and hERG screening for drug-induced torsades de pointes","volume":"119","author":"Hancox","year":"2008","journal-title":"Pharmacol Therap."},{"key":"B37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.pharmthera.2008.04.010","article-title":"Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk","volume":"119","author":"Gintant","year":"2008","journal-title":"Pharmacol Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0208321","DOI":"10.1371\/journal.pone.0208321","article-title":"Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation","volume":"13","author":"Aromolaran","year":"2018","journal-title":"PLoS ONE."},{"key":"B39","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/aps.2014.165","article-title":"The protease inhibitor atazanavir blocks hERG K+ channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane","volume":"36","author":"Han","year":"2015","journal-title":"Acta Pharmacol Sin."},{"key":"B40","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.cell.2017.03.048","article-title":"Cryo-EM structure of the open human ether-a-go-go-related K+ channel hERG","volume":"169","author":"Wang","year":"2017","journal-title":"Cell."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.3389\/fphar.2019.01572","article-title":"An update on the structure of hERG","volume":"10","author":"Butler","year":"2019","journal-title":"Front Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1021\/acs.jcim.9b00773","article-title":"Revealing molecular determinants of hERG blocker and activator binding","volume":"60","author":"Dickson","year":"2020","journal-title":"J Chem Inf Model."},{"key":"B43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/cpbi.3","article-title":"Comparative protein structure modeling using MODELLER","volume":"54","author":"Webb","year":"2016","journal-title":"Curr Protoc Bioinformatics."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1021\/ci4000739","article-title":"Interactions between voltage sensor and pore domains in a hERG K+ channel model from molecular simulations and the effects of a voltage sensor mutation","volume":"53","author":"Colenso","year":"2013","journal-title":"J Chem Inf Model."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1002\/prot.22711","article-title":"Improved side-chain torsion potentials for the Amber ff99SB protein force field","volume":"78","author":"Lindorff-Larsen","year":"2010","journal-title":"Proteins."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1021\/ct300342n","article-title":"An extension and further validation of an all-atomistic force field for biological membranes","volume":"8","author":"Jambeck","year":"2012","journal-title":"J Chem Theory Comput."},{"key":"B47","doi-asserted-by":"publisher","first-page":"7040","DOI":"10.1074\/jbc.RA117.000363","article-title":"Structural implications of hERG K+ channel block by a high affinity minimally-structured blocker","volume":"293","author":"Helliwell","year":"2018","journal-title":"J Biol Chem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.yjmcc.2014.05.013","article-title":"Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants","author":"Du","year":"2014","journal-title":"J Mol Cell Cardiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e001813","DOI":"10.1161\/JAHA.115.001813","article-title":"hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine","volume":"4","author":"Melgari","year":"2015","journal-title":"J Am Heart Assoc."},{"key":"B50","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bcp.2016.05.013","article-title":"Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking","volume":"113","author":"Zhang","year":"2016","journal-title":"Biochem Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1124\/jpet.120.000484","article-title":"COVID-19 drugs chloroquine and hydroxychloroquine, but not azithromycin and remdesivir, block hERG potassium channels","volume":"377","author":"Szendrey","year":"2021","journal-title":"J Pharmacol Exp Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.bbrc.2020.04.003","article-title":"Serine mutation of a conserved threonine in the hERG K+ channel S6-pore region leads to loss-of-function through trafficking impairment","volume":"526","author":"Al Moubarak","year":"2020","journal-title":"Biochem Biophys Res Comm."},{"key":"B53","unstructured":"Summary on Compassionate Use.2020"},{"key":"B54","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.1074\/jbc.M107345200","article-title":"The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations","volume":"277","author":"Ficker","year":"2002","journal-title":"J Biol Chem."},{"key":"B55","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.vascn.2004.06.003","article-title":"Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern","volume":"50","author":"Kirsch","year":"2004","journal-title":"J Pharmacol Toxicol Methods."},{"key":"B56","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.vascn.2010.02.007","article-title":"Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide","volume":"61","author":"Milnes","year":"2010","journal-title":"J Pharmacol Toxicol Methods."},{"key":"B57","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovas Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"106900","DOI":"10.1016\/j.vascn.2020.106900","article-title":"Revisiting the hERG safety margin after 20 years of routine hERG screening","volume":"105","author":"Leishman","year":"2020","journal-title":"J Pharmacol Toxicol Methods."},{"key":"B59","unstructured":"1172\n            Anon\n          Report on the Deliberation Results."},{"key":"B60","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.bpj.2019.10.010","article-title":"hERG function in light of structure","volume":"118","author":"Robertson","year":"2019","journal-title":"Biophys J."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e0217733","DOI":"10.1371\/journal.pone.0217733","article-title":"The molecular determinants of R-roscovitine block of hERG channels","volume":"14","author":"Cernuda","year":"2019","journal-title":"PLoS ONE."},{"key":"B62","doi-asserted-by":"publisher","first-page":"24182","DOI":"10.1038\/srep24182","article-title":"New potential binding determinant for hERG channel inhibitors","volume":"6","author":"Saxena","year":"2016","journal-title":"Sci Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1124\/mol.118.115642","article-title":"The pore-lipid interface: role of amino acid determinants of lipophilic access by ivabradine to the hERG1 pore domain","volume":"96","author":"Duff","year":"2019","journal-title":"Mol Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.yjmcc.2019.07.012","article-title":"Potent hERG channel inhibition by sarizotan, an investigative treatment for Rett Syndrome","volume":"135","author":"Cheng","year":"2019","journal-title":"J Mol Cell Cardiol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.bbrc.2006.01.008","article-title":"Erythromycin block of the HERG K+ channel: accessibility to F656 and Y652","volume":"341","author":"Duncan","year":"2006","journal-title":"Biochem Biophys Res Comm."},{"key":"B66","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/cpt.1303","article-title":"Assessment of multi-ion channel block in a Phase I Randomized study design: results of the CiPA phase I ECG biomarker validation study","volume":"105","author":"Vicente","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"B67","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/cts.12882","article-title":"Risk assessment of drug-induced long QT syndrome for some COVID-19 repurposed drugs","volume":"14","author":"Michaud","year":"2021","journal-title":"Clin Transl Sci."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.645172\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T04:21:13Z","timestamp":1620102073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.645172\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":67,"alternative-id":["10.3389\/fcvm.2021.645172"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.645172","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"article-number":"645172"}}